Viatris legal and compliance interviews test whether candidates understand how managing legal risk and regulatory compliance at a complex generics and off-patent pharmaceutical company differs from legal practice at a branded pharmaceutical company or other regulated industry – where the False Claims Act exposure from EpiPen's misclassification as a generic drug rather than a branded drug for Medicaid rebate purposes resulted in a $465 million settlement with the Department of Justice in 2017, demonstrating how Medicaid rebate classification decisions create federal False Claims Act liability when misclassification allows a manufacturer to underpay mandatory rebate obligations to state Medicaid programs, where FDA's promotional compliance framework under 21 CFR Part 202 creates legal risk in every commercial interaction between Viatris's sales force and healthcare providers when those interactions could be characterized as promoting products for unapproved uses or providing misleading efficacy information, and where paragraph IV ANDA patent certification litigation requires Viatris's legal team to manage patent challenge strategy decisions about which innovator patents to challenge, when to launch at risk before litigation is resolved, and how to evaluate settlement terms that balance certainty against the value of early market entry. Legal and compliance at Viatris spans FDA promotional compliance and OPDP enforcement risk management (where every Viatris promotional piece, sales representative training program, and speaker bureau arrangement requires review against the FDA promotional regulations that prohibit off-label promotion, require fair balance of risk information, and create Warning Letter exposure for promotional materials that the Division of Drug Marketing, Advertising, and Communications determines are false or misleading), Anti-Kickback Statute compliance and safe harbor management (where Viatris's commercial interactions with healthcare providers in speaker bureau arrangements, advisory board engagements, and promotional meal programs must be structured to qualify for AKS safe harbors for legitimate services at fair market value that distinguish permissible commercial relationships from illegal remuneration arrangements), ANDA paragraph IV patent certification strategy and at-risk launch decision-making (where challenging an innovator's patents through ANDA paragraph IV certification creates litigation risk that Viatris's legal team must assess when evaluating whether to launch generic products at risk before patent litigation is resolved), and FDCA Section 506C drug shortage notification compliance (where Viatris's obligations as a manufacturer of medically necessary drugs require legal review of notification triggers, content requirements, and FDA communication during active shortage situations).
Start your free Viatris Legal & Compliance practice session.
What interviewers actually evaluate
FDA Promotional Compliance, Anti-Kickback Statute Safe Harbor Management, and ANDA Patent Strategy
Viatris legal interviews probe whether candidates understand how pharmaceutical legal practice differs from general healthcare or regulatory law in the False Claims Act Medicaid rebate exposure (the 2017 EpiPen DOJ settlement illustrates how pharmaceutical pricing and rebate classification decisions create federal False Claims Act liability – where Mylan's classification of EpiPen as a generic drug rather than a branded drug for Medicaid rebate purposes reduced the mandatory rebate rate from 23.1% of average manufacturer price for branded drugs to 13% for generic drugs, resulting in Medicaid underpayments that the DOJ characterized as false claims to federal healthcare programs, and where the settlement's $465 million payment demonstrated that Medicaid rebate calculation decisions have liability consequences that extend well beyond the commercial and compliance teams who make the classification judgment), the FDA promotional compliance enforcement relationship (the Division of Drug Marketing, Advertising, and Communications issues public Warning Letters and Untitled Letters when FDA determines that pharmaceutical promotional materials make false or misleading claims, omit required fair balance risk information, or promote products for uses not approved in the FDA labeling – creating a regulatory enforcement dynamic where Viatris's legal team must assess the promotional compliance risk in materials before they are used and respond to FDA enforcement correspondence that creates public reputational consequences beyond the regulatory response itself), and the ANDA patent litigation strategic complexity (paragraph IV certification patent challenges require Viatris's legal team to develop a litigation strategy for multi-year patent disputes against well-resourced innovator pharmaceutical companies, assess when the litigation risk profile supports launching generic product at risk before the court resolves the patent challenge, and evaluate settlement offers that may provide authorized generic agreements, market entry dates, or royalty structures as alternatives to continued litigation uncertainty).
The Anti-Kickback Statute creates a compliance overlay on every commercial interaction that does not have a parallel in most other industries: the statute's broad prohibition on remuneration offered to influence healthcare provider prescribing decisions means that Viatris's legal team must assess the safe harbor qualification of arrangements that commercial teams design for business development purposes, where a speaker bureau arrangement that exceeds fair market value for the physician speaker's services, a meal that exceeds the nominal value threshold during a sales detail, or an advisory board engagement where the physician's clinical input is not genuinely sought could create AKS liability that the legal team must identify before the arrangement is implemented.
What gets scored in every session
Specific, sentence-level feedback.
| Dimension | What it measures | How to answer |
|---|---|---|
| False Claims Act Medicaid rebate compliance and government investigation management | Do you understand how to assess Viatris's False Claims Act exposure from Medicaid rebate classification and calculation decisions – how to conduct a privileged review of EpiPen-style rebate classification decisions that may have resulted in underpayment of Medicaid rebate obligations, what the internal investigation framework is when the government contacts Viatris regarding a rebate calculation issue versus when Viatris discovers a potential rebate miscalculation through internal audit, and how to structure the voluntary self-disclosure analysis that weighs the liability reduction from proactive disclosure against the risk of triggering a broader government investigation that self-disclosure may initiate? We flag legal answers that describe Medicaid rebate compliance as a finance and regulatory affairs issue without engaging with the False Claims Act liability framework and government investigation management that the EpiPen settlement illustrates. | AMP and best price calculation legal review, FCA voluntary self-disclosure analysis, government investigation privilege and cooperation strategy |
| FDA promotional compliance review and OPDP enforcement response | Can you describe how to structure Viatris's promotional material review process to manage FDA OPDP enforcement risk – what the medical, legal, and regulatory review workflow is for new promotional pieces before they are used with healthcare providers, how to assess whether a proposed promotional claim is adequately substantiated by the clinical data in the product labeling versus whether it constitutes a misleading superiority claim requiring additional clinical evidence, and how to respond when FDA's OPDP issues an Untitled Letter or Warning Letter alleging that a Viatris promotional piece makes false or misleading claims, including the response strategy for minimizing reputational damage when Warning Letters are publicly posted on FDA's website? We score whether your promotional compliance analysis engages with the specific substantiation and fair balance requirements that distinguish compliant from non-compliant pharmaceutical promotional materials. | Promotional claim substantiation assessment, MLR review workflow design, OPDP Warning Letter response strategy |
| Anti-Kickback Statute safe harbor compliance and commercial program review | Do you understand how to review Viatris's commercial programs against Anti-Kickback Statute safe harbor requirements – how to assess whether a proposed speaker bureau honorarium for a physician speaker qualifies for the personal services safe harbor by meeting the fair market value, legitimate services, and compensation not determined by referral volume requirements, what the legal analysis is for a meal program where sales representatives are reporting meal expenses that individually fall within policy limits but collectively suggest a pattern of HCP entertainment that may not qualify for the nominal value safe harbor, and how to design the corrective action when an internal compliance review identifies that a regional speaker bureau program has been paying honoraria above established fair market value ranges? We detect legal answers that describe AKS compliance as policy documentation without engaging with the specific safe harbor elements and fact pattern analysis that determine whether a commercial arrangement creates AKS liability. | Speaker bureau safe harbor element analysis, meal program pattern-of-conduct review, AKS corrective action program design |
| ANDA paragraph IV patent litigation strategy and at-risk launch decision | Can you describe how to develop the legal strategy for an ANDA paragraph IV certification challenge against an innovator pharmaceutical company – how to assess the litigation risk profile of the innovator's patents based on prosecution history, claim breadth, and prior art that Viatris's ANDA filing identified, what the legal framework is for evaluating whether to launch the generic product at risk before the court resolves the patent challenge including the contingent liability from potential infringement damages if the patent is upheld, and how to evaluate a settlement proposal from the innovator that offers an authorized generic agreement and a negotiated market entry date in exchange for abandoning the patent challenge? We flag legal answers that treat ANDA patent litigation as standard patent infringement defense without engaging with the at-risk launch decision framework and settlement valuation that distinguish generic pharmaceutical patent litigation strategy from other IP litigation contexts. | Patent challenge claim strength assessment, at-risk launch contingent liability quantification, settlement versus continued litigation NPV analysis |
How a session works
Step 1: Choose a Viatris legal scenario – False Claims Act Medicaid rebate compliance and government investigation management, FDA promotional compliance review and OPDP enforcement response, Anti-Kickback Statute safe harbor compliance for commercial programs, or ANDA paragraph IV patent litigation strategy and at-risk launch decision.
Step 2: The AI interviewer asks realistic Viatris legal questions: how you would structure Viatris's privileged internal investigation when the DOJ issues a civil investigative demand seeking documents related to Medicaid rebate calculations for EpiPen over the past seven years, including what the litigation hold procedures are for preserving documents responsive to the demand, how to assess whether Viatris's rebate calculation methodology for EpiPen has followed the AMP and best price definitions correctly or whether there are calculation positions that could be characterized as false claims to Medicaid, and what the decision framework is for whether to engage in early settlement discussions with the DOJ versus contesting the CID scope through legal challenge while the internal review continues; how you would advise Viatris's commercial team that a proposed speaker bureau arrangement for a physician gastroenterologist who prescribes several Viatris generic products would have the physician speak at programs in markets where Viatris's sales force has significant prescriber targeting overlap with the speaker's patient population, including how to evaluate whether the honorarium amount is supported by a current fair market value analysis, what the disclosure obligations are under the Sunshine Act for speaker payments, and what the indicators are that the arrangement may be intended to reward prescribing rather than compensate for legitimate speaking services; or how you would manage the patent litigation strategy when a court rules in favor of the innovator in a paragraph IV challenge for a generic product that Viatris launched at risk 90 days ago, including how to assess the damages exposure from the at-risk launch period, what the negotiated resolution options are that might include a royalty arrangement or supply agreement with the innovator, and how to manage the commercial and operational consequences of a court-ordered injunction requiring Viatris to stop distributing the at-risk launch product.
Step 3: You respond as you would in the actual interview. The system scores your answer on False Claims Act compliance management, FDA promotional enforcement response, AKS safe harbor analysis, and ANDA patent strategy.
Step 4: You get sentence-level feedback on what demonstrated genuine pharmaceutical legal expertise and what needs stronger AKS safe harbor element analysis or FCA investigation management specificity.
Frequently Asked Questions
What was the EpiPen DOJ settlement and what compliance lessons does it illustrate?
In 2017, Mylan (now Viatris) settled False Claims Act allegations with the Department of Justice for $465 million related to Medicaid rebate misclassification of EpiPen. The government alleged that Mylan had classified EpiPen as a generic drug for Medicaid rebate purposes, resulting in payment of the 13% generic drug rebate rate rather than the 23.1% branded drug minimum rebate rate. The misclassification resulted in underpayments to state Medicaid programs because EpiPen's clinical profile as a branded auto-injector device with no therapeutic equivalent available in the same product category warranted branded drug classification. The settlement illustrates how pharmaceutical rebate classification decisions create Federal False Claims Act exposure when the classification results in systematic underpayment of mandatory government program rebates, and how the liability from such decisions can substantially exceed the commercial benefit received from the favorable classification during the period of misclassification.
How does FDA's OPDP enforce prescription drug advertising regulations?
FDA's Office of Prescription Drug Promotion enforces the prescription drug advertising regulations under 21 CFR Part 202 through review of promotional materials submitted by pharmaceutical companies and through monitoring of promotional materials that reach FDA's attention through competitors, healthcare providers, or internal company submissions. When OPDP identifies a promotional piece that it determines makes false or misleading claims, omits required fair balance risk information, or promotes a product for unapproved uses, it issues enforcement correspondence ranging from Untitled Letters for less serious violations to Warning Letters for more serious violations requiring prompt corrective action. Warning Letters are publicly posted on FDA's website, creating reputational consequences that affect prescriber confidence in the company's commercial integrity and that may prompt competitor attention and payer scrutiny of the company's promotional practices.
What are the AKS safe harbor requirements for pharmaceutical speaker bureau programs?
The personal services safe harbor for Anti-Kickback Statute purposes requires that speaker bureau arrangements meet several elements: the arrangement must be set out in a written agreement signed by the parties before services are rendered, the compensation must be set in advance and not be determined in a manner that takes into account the volume or value of referrals from the speaker, and the services must be legitimately needed and the compensation must not exceed fair market value for services of a similar nature. Pharmaceutical companies typically establish fair market value ranges for physician speakers based on credentials, specialty, and geographic market, and document the legitimate educational purpose of each speaker program. The compliance risk arises when speakers are paid honoraria that exceed their established fair market value range, when programs are held without genuine educational content, or when speakers receive compensation at rates that suggest the honorarium is designed to reward prescribing relationships rather than legitimate speaking services.
How does ANDA paragraph IV patent litigation work?
When a generic pharmaceutical company files an ANDA with FDA and certifies under paragraph IV that patents listed in FDA's Orange Book for the reference listed drug are invalid or will not be infringed by the generic product, the patent holder has 45 days to file a patent infringement lawsuit that automatically triggers a 30-month stay of FDA approval. During the 30-month stay, the patent litigation proceeds with the generic company defending its ANDA's non-infringement or invalidity position. If the litigation is resolved in the generic company's favor or the 30-month stay expires without final judgment, FDA can approve the ANDA. The decision to launch at risk before final court resolution is a legal and business judgment about whether the probability-weighted value of early market entry exceeds the contingent infringement damages exposure if the innovator ultimately prevails.
What are Viatris's obligations under FDCA Section 506C for drug shortage notification?
FDCA Section 506C requires manufacturers of certain pharmaceutical products to notify FDA at least six months in advance of a discontinuation or significant interruption of manufacturing that is likely to lead to a drug shortage. The notification requirement applies to drugs that FDA determines are medically necessary – a determination that considers whether adequate therapeutic alternatives are available. When a manufacturing disruption is anticipated, Viatris's legal and regulatory team must assess whether the affected product meets the medically necessary threshold and, if so, ensure that the required notification is submitted to FDA within the statutory timeframe. Failure to provide timely notification creates regulatory consequences and may affect Viatris's relationship with FDA's drug shortage staff who coordinate supply continuity responses when shortages affect patient access.
Also practice
One full session free. No account required. Real, specific feedback.
